GPC Prostate Drug Needs More Data, FDA Panel Says
U.S. regulators should wait for final survival data before deciding whether to approve
GPC Biotech's proposed prostate cancer pill Orplatna, an advisory panel said on Tuesday in a 12-0 vote.
The Food and Drug Administration usually follows panel recommendations. The agency is expected to make a final decision on whether to clear Orplatna by mid-August.